Ayala Pharmaceuticals, Inc. (AYLA) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/15/21
Ayala Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 11/15/21
Earnings Preview: Ayala Pharmaceuticals, Inc. (AYLA) Q3 Earnings Expected to DeclineZacks Investment Research • 11/09/21
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor ConferencesGlobeNewsWire • 09/02/21
Ayala Pharmaceuticals to Present Clinical Data from Ongoing Phase 2 ACCURACY Trial and New Preclinical Results from Combination Study of AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021GlobeNewsWire • 09/01/21
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/13/21
Ayala Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/21
Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should KnowZacks Investment Research • 08/05/21
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/14/21
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple MyelomaGlobeNewsWire • 04/21/21
Ayala Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 03/25/21
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue TumorsBenzinga • 02/19/21
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast CancerGlobeNewsWire • 01/28/21
Ayala Pharmaceuticals to Present at Noble Capital Markets 17th Annual Small & Microcap Virtual Investor ConferenceGlobeNewsWire • 01/13/21
Ayala Pharmaceuticals to Present at the Virtual H.C. Wainwright Bioconnect ConferenceGlobeNewsWire • 01/05/21
Ayala Pharmaceuticals to Accelerate Development of AL102 for the Treatment of Desmoid Tumors in Pivotal Phase 2/3 StudyGlobeNewsWire • 01/04/21
Ayala Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 11/17/20